Neuroprotective Effects of Free Radical Scavengers in Stroke

[1]  N. Plesnila,et al.  Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia , 2007, Cell Death and Differentiation.

[2]  A. Shuaib,et al.  Therapeutic strategies for the treatment of stroke. , 2006, Drug discovery today.

[3]  G. Hankey.  Neuroprotection for acute ischaemic stroke: hope reignited , 2006, The Lancet Neurology.

[4]  J. Grotta,et al.  NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[5]  S. Starkman,et al.  Physician-Investigator Phone Elicitation of Consent in the Field: A Novel Method To Obtain Explicit Informed Consent For Prehospital Clinical Research , 2006, Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors.

[6]  M. A. Moro,et al.  Mitochondrial respiratory chain and free radical generation in stroke. , 2005, Free radical biology & medicine.

[7]  T. Ikeda,et al.  Short-Term Administration of a New Free Radical Scavenger, Edaravone, Is More Effective Than its Long-Term Administration for the Treatment of Neonatal Hypoxic–Ischemic Encephalopathy , 2005, Stroke.

[8]  Ning Zhang,et al.  Edaravone Reduces Early Accumulation of Oxidative Products and Sequential Inflammatory Responses After Transient Focal Ischemia in Mice Brain , 2005, Stroke.

[9]  M. Plotkine,et al.  Antioxidant strategies in the treatment of stroke. , 2005, Free radical biology & medicine.

[10]  M. Alexandrova,et al.  Oxidative stress during the chronic phase after stroke. , 2005, Free radical biology & medicine.

[11]  María Angeles Peinado,et al.  The role of free radicals in cerebral hypoxia and ischemia. , 2005, Free radical biology & medicine.

[12]  C. Nito,et al.  Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. , 2005, European journal of pharmacology.

[13]  A. Green,et al.  Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. , 2005, Current drug targets. CNS and neurological disorders.

[14]  B. Schaller.  Introduction to serial reviews on free radicals and stroke. , 2005, Free radical biology & medicine.

[15]  S. Kuroda,et al.  Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia , 2004, Brain Research.

[16]  F. J. Romero,et al.  Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia. , 2004, European journal of pharmacology.

[17]  Lippincott Williams Wilkins,et al.  Major ongoing stroke trials. , 2004, Stroke.

[18]  D. Jackson,et al.  Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. , 2003, Pharmacology & therapeutics.

[19]  R. Graf,et al.  Ischaemic tolerance: a window to endogenous neuroprotection? , 2003, The Lancet.

[20]  R. Ridley,et al.  Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. , 2003, Stroke.

[21]  T. Nose,et al.  The antioxidant EPC-K1 ameliorates brain injury by inhibiting lipid peroxidation in a rat model of transient focal cerebral ischaemia , 2003, Acta Neurochirurgica.

[22]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[23]  D. DeLong,et al.  Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction , 2003, Cerebrovascular Diseases.

[24]  B. Siesjö,et al.  NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia , 2002, Brain Research.

[25]  B. Siesjö,et al.  Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A , 2002, Brain Research.

[26]  E. Ringelstein,et al.  The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke , 2002, Neurology.

[27]  D. Graham,et al.  Ebselen Protects Both Gray and White Matter in a Rodent Model of Focal Cerebral Ischemia , 2001, Stroke.

[28]  A. Buchan,et al.  NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat , 2001, Brain Research.

[29]  D. Corbett,et al.  Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke , 2001, Neuropharmacology.

[30]  R. Ridley,et al.  NXY-059, a Free Radical–Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species , 2001, Stroke.

[31]  K. R. Maples,et al.  Comparison of the radical trapping ability of PBN, S-PBN and NXY-059 , 2001, Free radical research.

[32]  J. Orgogozo,et al.  Tirilazad for acute ischaemic stroke. , 2001, The Cochrane database of systematic reviews.

[33]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[34]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[35]  Junying Yuan,et al.  Apoptosis in the nervous system , 2000, Nature.

[36]  A. Shuaib,et al.  Neuroprotection by 2-h Postischemia Administration of Two Free Radical Scavengers, α-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in Rats Subjected to Focal Embolic Cerebral Ischemia , 2000, Experimental Neurology.

[37]  S. Kuroda,et al.  Neuroprotective Effects of a Novel Nitrone, NXY-059, after Transient Focal Cerebral Ischemia in the Rat , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  H. Kikuchi,et al.  Ebselen in Acute Middle Cerebral Artery Occlusion: A Placebo-Controlled, Double-Blind Clinical Trial , 1999, Cerebrovascular Diseases.

[39]  H. Reulen,et al.  Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. , 1999, Neurosurgery.

[40]  H. Reulen,et al.  Monotherapy with dextromethorphan or tirilazad – but not a combination of both – improves outcome after transient focal cerebral ischemia in rats , 1998, Experimental Brain Research.

[41]  K. Takakura,et al.  Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. , 1998, Stroke.

[42]  D. Graham,et al.  Neuroprotective efficacy of ebselen, an anti‐oxidant with anti‐inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion , 1997, British journal of pharmacology.

[43]  P. Chan,et al.  Role of oxidants in ischemic brain damage. , 1996, Stroke.

[44]  R. Busto,et al.  Journal of Cerebral Blood Flow and Metabolism Simultaneous Measurement of Salicylate Hydroxylation and Glutamate Release in the Penumbral Cortex following Transient Middle Cerebral Artery Occlusion in Rats , 2022 .

[45]  Zheng-lai Wu,et al.  Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. , 1995, Stroke.

[46]  Zheng-lai Wu,et al.  Stroke in the People's Republic of China. II. Meta-analysis of hypertension and risk of stroke. , 1995, Stroke.

[47]  E. Lancelot,et al.  Detection of hydroxyl radicals in rat striatum during transient focal cerebral ischemia: possible implication in tissue damage , 1995, Neuroscience Letters.

[48]  D. Graham,et al.  The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat , 1995, Neuroscience Letters.

[49]  Jun Chen,et al.  Human Copper‐Zinc Superoxide Dismutase Transgenic Mice Are Highly Resistant to Reperfusion Injury After Focal Cerebral Ischemia , 1994, Stroke.

[50]  J. Kehrer.  Free radicals as mediators of tissue injury and disease. , 1993, Critical reviews in toxicology.

[51]  M. Moskowitz,et al.  Oxygen radicals in cerebral ischemia. , 1992, The American journal of physiology.

[52]  Y. Yamamoto,et al.  Action of ebselen as an antioxidant against lipid peroxidation. , 1992, Biochemical pharmacology.

[53]  C. Epstein,et al.  Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  E. Stadtman,et al.  Metal-catalyzed oxidation of proteins. Physiological consequences. , 1991, The Journal of biological chemistry.

[55]  C. Manso.  [Oxygen free radicals]. , 1989, Acta medica portuguesa.

[56]  C. Agardh,et al.  Free radicals and brain damage. , 1989, Cerebrovascular and brain metabolism reviews.

[57]  Andrew P. Duchon,et al.  Oxygen free radical involvement in ischemia and reperfusion injury to brain , 1988, Neuroscience Letters.

[58]  P. Kochanek,et al.  Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. , 1986, Stroke.

[59]  R. Busto,et al.  Lipid Peroxidation In Vivo Induced by Reversible Global Ischemia in Rat Brain , 1984, Journal of neurochemistry.

[60]  J. Crapo,et al.  Biology of disease: free radicals and tissue injury. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[61]  E. Flamm,et al.  Free radicals in cerebral ischemia. , 1978, Stroke.